The Cost-utility Analysis of 18-Fluoro-2-Deoxyglucose Positron Emission Tomography in the Diagnosis of Recurrent Nasopharyngeal Carcinoma

Ruoh Fang Yen, Ming Fang Yen, Ruey Long Hong, Kai Yuan Tzen, Chun Ru Chien, Tony Hsiu Hsi Chen

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Rationale and Objectives: 18-Fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) is effective but costly in the early detection of recurrence for nasopharyngeal carcinoma (NPC) in patients after treatment. In this study, we developed a decision tree model to analyze the cost utility of 18F-FDG PET in detecting loco-regional recurrences for NPC patients after therapy. Materials and Methods: The analysis for cost utility is based on the decision-tree model for three different strategies: 1) magnetic resonance imaging (MRI)-only, 2) PET-only, and 3) MRI-PET (performing PET if MRI result is uncertain). Sensitivity analyses have been performed to examine changes in the cost ratio of PET/MRI and the probability of uncertain MRI. Results: After inputting the data for utilities and life expectancies into the decision tree model, the quality-adjusted life expectancies turn out to be 16.16 quality-adjusted life-years (QALYs) for strategy 1, 16.70 QALYs for strategy 2, and 17.35 QALYs for strategy 3. The additional cost per additional QALYs for strategy 3 relative to strategy 1 is calculated to be US $462. Strategy 3 dominates over strategy 2 because strategy 3 costs less and yields more QALYs than strategy 2. If the cost ratio of PET/MRI is less than 1.85 or the probability of uncertain MRI is greater than 73%, then the PET-only strategy becomes more cost-effective than the MRI-PET strategy. Conclusion: Our analysis shows that the MRI-PET strategy is the most cost-effective for now. It is likely the PET-only strategy will become the most cost-effective for recurrent NPC in patients in the near future as the cost of PET has decreased in a faster rate than the cost of MRI.

Original languageEnglish
Pages (from-to)54-60
Number of pages7
JournalAcademic Radiology
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 2009
Externally publishedYes

Fingerprint

Deoxyglucose
Positron-Emission Tomography
Cost-Benefit Analysis
Magnetic Resonance Imaging
Quality-Adjusted Life Years
Costs and Cost Analysis
Decision Trees
Fluorodeoxyglucose F18
Life Expectancy
Nasopharyngeal carcinoma
Recurrence
Quality of Life

Keywords

  • 18F-FDG PET
  • cost-utility analysis
  • decision tree model
  • Nasopharyngeal carcinoma
  • recurrence

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

The Cost-utility Analysis of 18-Fluoro-2-Deoxyglucose Positron Emission Tomography in the Diagnosis of Recurrent Nasopharyngeal Carcinoma. / Yen, Ruoh Fang; Yen, Ming Fang; Hong, Ruey Long; Tzen, Kai Yuan; Chien, Chun Ru; Chen, Tony Hsiu Hsi.

In: Academic Radiology, Vol. 16, No. 1, 01.2009, p. 54-60.

Research output: Contribution to journalArticle

Yen, Ruoh Fang ; Yen, Ming Fang ; Hong, Ruey Long ; Tzen, Kai Yuan ; Chien, Chun Ru ; Chen, Tony Hsiu Hsi. / The Cost-utility Analysis of 18-Fluoro-2-Deoxyglucose Positron Emission Tomography in the Diagnosis of Recurrent Nasopharyngeal Carcinoma. In: Academic Radiology. 2009 ; Vol. 16, No. 1. pp. 54-60.
@article{398f884ae038447f8848d73af3cc7b72,
title = "The Cost-utility Analysis of 18-Fluoro-2-Deoxyglucose Positron Emission Tomography in the Diagnosis of Recurrent Nasopharyngeal Carcinoma",
abstract = "Rationale and Objectives: 18-Fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) is effective but costly in the early detection of recurrence for nasopharyngeal carcinoma (NPC) in patients after treatment. In this study, we developed a decision tree model to analyze the cost utility of 18F-FDG PET in detecting loco-regional recurrences for NPC patients after therapy. Materials and Methods: The analysis for cost utility is based on the decision-tree model for three different strategies: 1) magnetic resonance imaging (MRI)-only, 2) PET-only, and 3) MRI-PET (performing PET if MRI result is uncertain). Sensitivity analyses have been performed to examine changes in the cost ratio of PET/MRI and the probability of uncertain MRI. Results: After inputting the data for utilities and life expectancies into the decision tree model, the quality-adjusted life expectancies turn out to be 16.16 quality-adjusted life-years (QALYs) for strategy 1, 16.70 QALYs for strategy 2, and 17.35 QALYs for strategy 3. The additional cost per additional QALYs for strategy 3 relative to strategy 1 is calculated to be US $462. Strategy 3 dominates over strategy 2 because strategy 3 costs less and yields more QALYs than strategy 2. If the cost ratio of PET/MRI is less than 1.85 or the probability of uncertain MRI is greater than 73{\%}, then the PET-only strategy becomes more cost-effective than the MRI-PET strategy. Conclusion: Our analysis shows that the MRI-PET strategy is the most cost-effective for now. It is likely the PET-only strategy will become the most cost-effective for recurrent NPC in patients in the near future as the cost of PET has decreased in a faster rate than the cost of MRI.",
keywords = "18F-FDG PET, cost-utility analysis, decision tree model, Nasopharyngeal carcinoma, recurrence",
author = "Yen, {Ruoh Fang} and Yen, {Ming Fang} and Hong, {Ruey Long} and Tzen, {Kai Yuan} and Chien, {Chun Ru} and Chen, {Tony Hsiu Hsi}",
year = "2009",
month = "1",
doi = "10.1016/j.acra.2008.06.012",
language = "English",
volume = "16",
pages = "54--60",
journal = "Academic Radiology",
issn = "1076-6332",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - The Cost-utility Analysis of 18-Fluoro-2-Deoxyglucose Positron Emission Tomography in the Diagnosis of Recurrent Nasopharyngeal Carcinoma

AU - Yen, Ruoh Fang

AU - Yen, Ming Fang

AU - Hong, Ruey Long

AU - Tzen, Kai Yuan

AU - Chien, Chun Ru

AU - Chen, Tony Hsiu Hsi

PY - 2009/1

Y1 - 2009/1

N2 - Rationale and Objectives: 18-Fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) is effective but costly in the early detection of recurrence for nasopharyngeal carcinoma (NPC) in patients after treatment. In this study, we developed a decision tree model to analyze the cost utility of 18F-FDG PET in detecting loco-regional recurrences for NPC patients after therapy. Materials and Methods: The analysis for cost utility is based on the decision-tree model for three different strategies: 1) magnetic resonance imaging (MRI)-only, 2) PET-only, and 3) MRI-PET (performing PET if MRI result is uncertain). Sensitivity analyses have been performed to examine changes in the cost ratio of PET/MRI and the probability of uncertain MRI. Results: After inputting the data for utilities and life expectancies into the decision tree model, the quality-adjusted life expectancies turn out to be 16.16 quality-adjusted life-years (QALYs) for strategy 1, 16.70 QALYs for strategy 2, and 17.35 QALYs for strategy 3. The additional cost per additional QALYs for strategy 3 relative to strategy 1 is calculated to be US $462. Strategy 3 dominates over strategy 2 because strategy 3 costs less and yields more QALYs than strategy 2. If the cost ratio of PET/MRI is less than 1.85 or the probability of uncertain MRI is greater than 73%, then the PET-only strategy becomes more cost-effective than the MRI-PET strategy. Conclusion: Our analysis shows that the MRI-PET strategy is the most cost-effective for now. It is likely the PET-only strategy will become the most cost-effective for recurrent NPC in patients in the near future as the cost of PET has decreased in a faster rate than the cost of MRI.

AB - Rationale and Objectives: 18-Fluoro-2-deoxyglucose (18F-FDG) positron emission tomography (PET) is effective but costly in the early detection of recurrence for nasopharyngeal carcinoma (NPC) in patients after treatment. In this study, we developed a decision tree model to analyze the cost utility of 18F-FDG PET in detecting loco-regional recurrences for NPC patients after therapy. Materials and Methods: The analysis for cost utility is based on the decision-tree model for three different strategies: 1) magnetic resonance imaging (MRI)-only, 2) PET-only, and 3) MRI-PET (performing PET if MRI result is uncertain). Sensitivity analyses have been performed to examine changes in the cost ratio of PET/MRI and the probability of uncertain MRI. Results: After inputting the data for utilities and life expectancies into the decision tree model, the quality-adjusted life expectancies turn out to be 16.16 quality-adjusted life-years (QALYs) for strategy 1, 16.70 QALYs for strategy 2, and 17.35 QALYs for strategy 3. The additional cost per additional QALYs for strategy 3 relative to strategy 1 is calculated to be US $462. Strategy 3 dominates over strategy 2 because strategy 3 costs less and yields more QALYs than strategy 2. If the cost ratio of PET/MRI is less than 1.85 or the probability of uncertain MRI is greater than 73%, then the PET-only strategy becomes more cost-effective than the MRI-PET strategy. Conclusion: Our analysis shows that the MRI-PET strategy is the most cost-effective for now. It is likely the PET-only strategy will become the most cost-effective for recurrent NPC in patients in the near future as the cost of PET has decreased in a faster rate than the cost of MRI.

KW - 18F-FDG PET

KW - cost-utility analysis

KW - decision tree model

KW - Nasopharyngeal carcinoma

KW - recurrence

UR - http://www.scopus.com/inward/record.url?scp=57049084026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57049084026&partnerID=8YFLogxK

U2 - 10.1016/j.acra.2008.06.012

DO - 10.1016/j.acra.2008.06.012

M3 - Article

VL - 16

SP - 54

EP - 60

JO - Academic Radiology

JF - Academic Radiology

SN - 1076-6332

IS - 1

ER -